Investors & Media

For media inquiries,
please contact:

Alex Van Rees
SmithSolve
973-442-1555 x111
Send an email

In the News

Dicerna has been featured frequently in the media. Please browse select news coverage to read more about Dicerna and its next generation RNAi approach to developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules.